Framework to calculate <sup>225</sup> Ac, <sup>177</sup> Lu, and <sup>161</sup> Tb radiation dose and biological effect in metastatic castration‐resistant prostate cancer treatment
DPKs and BECKs of <sup>2</sup> <sup>2</sup>⁵Ac, ¹⁷⁷Lu, and ¹⁶¹Tb were developed to quantify cellular-level dose distributions and biological efficacy, revealing micrometer-scale heterogeneity accentuated by short-range emissions (α, CEs, AEs). Results demonstrate ¹⁶¹Tb's optimal performance for micrometastases-surpassing ¹⁷⁷Lu's efficacy with lower toxicity than <sup>2</sup> <sup>2</sup>⁵Ac-while relative biological effectiveness predicts activity requirements: <sup>2</sup> <sup>2</sup>⁵Ac << ¹⁶¹Tb < ¹⁷⁷Lu.
Authors
- Ting‐Yim Lee (ORCID: https://orcid.org/0000-0001-7605-9752)
- Glenn Bauman (ORCID: https://orcid.org/0000-0002-5279-7360)
- Danny De Sarno
- Shahin Ghaseminejad
Institutions
- Western University (CA)
- Lawson Health Research Institute (CA)
- London Health Sciences Centre (CA)
Publication Details
- Journal
- Medical Physics
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1002/mp.18035
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canada Foundation for Innovation
- Canadian Institutes of Health Research